John Woock - Axonics Modulation Chief Marketing Officer
Executive
Dr. John Woock, Ph.D is the Chief Marketing Officer of the company. He has served as our Chief Marketing Officer since June 2018. Prior to that time, Mr. Woock served as our VP, Global Marketing and Clinical Operations from January 2017 to May 2018 and our VP, Product Marketing from June 2014 to December 2016. Before working with our company, he was a postdoctoral fellow at the Stanford Biodesign Program at Stanford University from August 2013 to June 2014 since 2017.
| Age | 41 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 949 396 6322 |
| Web | https://www.axonics.com |
John Woock Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Woock against Axonics Modulation stock is an integral part of due diligence when investing in Axonics Modulation. John Woock insider activity provides valuable insight into whether Axonics Modulation is net buyers or sellers over its current business cycle. Note, Axonics Modulation insiders must abide by specific rules, including filing SEC forms every time they buy or sell Axonics Modulation'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Woock over a year ago Exercise or conversion by John Woock of 28000 shares of Axonics Modulation subject to Rule 16b-3 | ||
John Woock over a year ago Axonics Modulation exotic insider transaction detected | ||
John Woock over a year ago Sale by John Woock of 100 shares of Axonics Modulation |
Axonics Modulation Management Efficiency
Axonics Modulation's management efficiency ratios could be used to measure how well Axonics Modulation manages its routine affairs as well as how well it operates its assets and liabilities.Axonics Modulation Technologies currently holds 27.62 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics Modulation has a current ratio of 10.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Axonics Modulation's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sumi Shrishrimal | iRhythm Technologies | 45 | |
| Tracy Founds | Glaukos Corp | N/A | |
| Christopher Lewis | Glaukos Corp | N/A | |
| Marc Rosenbaum | iRhythm Technologies | 52 | |
| Jeff Bertolini | Si Bone | N/A | |
| Martha MD | Neuropace | 68 | |
| MS MD | iRhythm Technologies | 50 | |
| Julie Andrews | Orthofix Medical | 54 | |
| Jessica Smith | Integra LifeSciences Holdings | N/A | |
| Gali Attias | Nano X Imaging | 46 | |
| Michael JD | Si Bone | 47 | |
| Mathieu Aussermeier | Integra LifeSciences Holdings | N/A | |
| Chris Tyson | Monogram Orthopaedics Common | N/A | |
| Philip Kowalczyk | LivaNova PLC | N/A | |
| Kenneth Washington | Medtronic PLC | 65 | |
| Chad Patterson | iRhythm Technologies | 42 | |
| Andres Cedron | Orthofix Medical | 44 | |
| Leah Akin | Neuropace | N/A | |
| MBA MD | Nano X Imaging | N/A | |
| Stephanie Walsh | Orthofix Medical | N/A | |
| John Ferrell | CONMED | 56 | |
Management Performance
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 |
Axonics Modulation Leadership Team
Elected by the shareholders, the Axonics Modulation's board of directors comprises two types of representatives: Axonics Modulation inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics Modulation's management team and ensure that shareholders' interests are well served. Axonics Modulation's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics Modulation's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfred Ford, Chief Commercial Officer | ||
| Danny Dearen, Chief Operating and Financial Officer | ||
| MD MAS, Chief Officer | ||
| Raymond Cohen, CEO, Director | ||
| Rinda Sama, Chief Officer | ||
| JD Esq, General VP | ||
| Aaron Pettit, General Officer | ||
| Kari Keese, Chief Officer | ||
| John Woock, Chief Marketing Officer | ||
| Neil Bhalodkar, Vice Relations | ||
| Guangqiang Jiang, Chief Officer |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics Modulation a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 51.11 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 87.22 % | |||
| Number Of Shares Shorted | 3.31 M | |||
| Price To Earning | (10.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Axonics Stock
If you are still planning to invest in Axonics Modulation check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Axonics Modulation's history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |